J&J nasal spray gets U.S. approval as first new type of anti-depressant in decades

(Reuters) – The U.S. Food and Drug Administration on Tuesday said it approved a Johnson & Johnson nasal spray antidepressant for people resistant to other treatments but placed restrictions on use of the drug, which it warned could be misused and abused.

FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake/File Photo

The approval of nasal spray esketamine marks the first new type of treatment for depression in more than 30 years and has raised hopes for its relatively fast action and ability to treat some otherwise unreachable patients.

Esketamine would be sold under the brand name Spravato and is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”. To prevent abuse, patients must take the drug in a doctor’s office or medical facility and cannot take it home.

Currently available anti-depressants such as Eli Lilly and Co’s Prozac work on neurotransmitters like serotonin and norepinephrine, but most drugs take at least four weeks to show effect and fail to produce an adequate response in about 30 percent to 40 percent of patients with major depressive disorder (MDD).

“Spravato has the potential to change the treatment paradigm and offer new hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies,” said Mathai Mammen, global head of J&J’s Janssen Research & Development.

Spravato has been touted as an asset with blockbuster potential and is expected to improve investor sentiment toward the growth prospects of J&J’s pharma unit Janssen, as its top-selling rheumatoid arthritis drug Remicade faces increased competition from cheaper biosimilars.

The treatment carries a boxed warning – FDA’s harshest – flagging the risk for sedation and difficulty with attention, judgment and thinking, abuse and misuse, and suicidal thoughts after administration of the drug.

Spravato is absorbed by the lining of the nasal passages and into the blood stream and will be used along with a newly prescribed oral antidepressant, Johnson & Johnson said in a statement here

During clinical trials, Spravato was found to relieve depression symptoms within 24 hours in some patients, said Janssen spokesman Greg Panico.

The approval comes after an FDA advisory panel in February voted heavily in favor of the drug esketamine, saying its benefits outweighed the risks.

However, the panel members echoed concerns raised by FDA staffers regarding the increased risk of sedation, dissociation and higher blood pressure observed in the study.

The drug is also being tested in patients with depression who are at a high risk of committing suicide.

Recent research shows that depression involves deterioration of the quality and number of nerve cell connections in areas of the brain related to mood. J&J’s drug helps restore these nerve cell connections in the brain, leading to an improvement in depression symptoms, according to the company. Over 300 million people globally live with major depressive disorders, and the incidence of attempted suicide in people with this condition is about 20-fold higher than that among those without the disorder.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Cynthia Osterman and Lisa Shumaker

Source

more recommended stories

  • FDA finds ‘significant violations’ at India’s Strides plant

    (Reuters) – The U.S. Food and.

  • U.N. wants more urgency in AIDS fight as gains and funding fade

    LONDON (Reuters) – The global fight.

  • Oklahoma seeks to hold J&J responsible for opioid crisis as trial ends

    NORMAN, Okla. (Reuters) – Lawyers for.

  • Healthy living may help offset genetic risk of dementia: study

    LONDON (Reuters) – Living healthily with.

  • Democrats take aim as Trump abandons drug pricing plan

    WASHINGTON (Reuters) – Democrats see U.S..

  • U.S. appeals court blocks Trump administration birth control exemptions

    (Reuters) – A federal appeals court.

  • China vows to tackle dead pig scam amid swine fever epidemic

    FILE PHOTO: Piglets are seen by.

  • Alberta joins Ontario in pulling some CannTrust weed products

    TORONTO (Reuters) – Alberta is placing.

  • Trump administration pushes U.S. at-home kidney care, transplant availability

    NEW YORK/WASHINGTON (Reuters) – The Trump.

  • U.S. appeals court signals sympathy to bid to strike down Obamacare

    NEW ORLEANS (Reuters) – A federal.

  • U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

    (Reuters) – A federal judge on.

  • Intra-Cellular drug fails one of two bipolar depression studies; shares fall

    (Reuters) – Intra-Cellular Therapies Inc said.

  • China reports new African swine fever outbreak in Guangxi region

    BEIJING (Reuters) – China’s southwestern region.

  • Weed ban means no Rocky Mountain high for Canada’s Calgary Stampede

    CALGARY, Alberta (Reuters) – Canada’s Calgary.

  • Weightlifting better at reducing heart fat than aerobic exercise

    Obese people who engaged in resistance.

  • Sydney’s city council reviews use of Bayer’s Roundup weed killer amid cancer fears

    SYDNEY (Reuters) – Sydney’s city council.

  • Bulgaria confirms two cases of African swine fever

    SOFIA (Reuters) – Bulgaria has confirmed.

  • FDA approves Karyopharm Therapeutics’ blood cancer drug

    (Reuters) – The U.S. Food and.

  • Facebook to tackle content with misleading health claims

    FILE PHOTO: The Facebook logo is.

  • FDA ties three deaths to Edwards Lifesciences’ recalled heart devices

    (Reuters) – The U.S. Food and.

  • India asks its states not to partner with Philip Morris-funded foundation

    NEW DELHI (Reuters) – India’s health.

  • U.S. federal court delays adoption of healthcare rule on abortion

    FILE PHOTO – A imaging table.

  • China tightens vaccine management after scandals

    FILE PHOTO – A nurse prepares.

  • U.S wages lost to unpaid family care to hit $147 billion by 2050

    As the U.S. population ages, the.

  • U.S. ‘gag rule’ linked to 40% jump in abortions in parts of Africa

    LONDON (Reuters) – A decades-old U.S..

  • Study shows major real-world impact of cervical cancer vaccines

    LONDON, June 26 (Reuters) – Vaccination.

  • Glyphosate use will eventually end, Merkel says

    German Chancellor Angela Merkel attends a.

  • Unproven stem cell therapies often peddled by doctors without training

    At U.S. clinics advertising unproven stem.

  • Teleflex recalls breathing tubes worldwide after reports of 4 deaths

    (Reuters) – Teleflex Inc said on.

  • In border camps, Syrians rely on doctors in trucks and tents

    AZAZ, Syria (Reuters) – The Syrian.

  • Thailand bans pig imports from Laos after African swine fever outbreak

    BANGKOK (Reuters) – Thailand will ban.

  • FDA approves drug for loss of sexual desire in women

    (Reuters) – The U.S. drug regulator.